Lipopolysaccharide-coated CuS nanoparticles promoted anti-cancer and anti-metastatic effect by immuno-photothermal therapy.

Jun-O Jin,Bian Jang,Junghwan Oh,Mingyeong Kang,Minseok Kwak,Li Xu,Wei Zhang,Ling Zeng,Madhappan S Moorthy

doi:10.18632/oncotarget.22331

Jun-O Jin, Bian Jang + Show 7 more

Open Access

https://doi.org/10.18632/oncotarget.22331

Copy DOI

Abstract

To meet the ultimate goal of cancer therapy, which is treating not only the primary tumor but also preventing metastatic cancer, the concept of combining immunotherapy with photothermal therapy (PTT) is gaining great interest. Here, we studied the new material, lipopolysaccharide (LPS) coated copper sulfide nanoparticles (LPS-CuS), for the immuno-photothermal therapy. We evaluated the effect of LPS-CuS for induction of apoptosis of CT26 cells and activation of dendritic cells. Moreover, the LPS-CuS and laser irradiation was examined anti-metastasis effect by liver metastasis model mouse in vivo. Through PTT, LPS-CuS induced elimination of CT26 tumor in BALB/c mice, which produced cancer antigens. In addition, released LPS and cancer antigen by PTT promoted dendritic cell activation in tumor draining lymph node (drLN), and consequently, enhanced the tumor antigen-specific immune responses. Finally, the primary tumor cured mice by LPS-CuS-mediated PTT completely resisted secondary tumor injection in the spleen and also prevented liver metastasis. Our results demonstrated the potential usage of LPS-CuS for the immuno-photothermal therapy against various types of cancer by showing the clear elimination of primary colon carcinoma with complete prevention of spleen and liver metastasis.

Highlights

To achieve success in cancer therapy, great endeavors have been devoted to cancer research all around the world
We evaluated the effect of LPS-coated copper sulfide nanoparticles (LPS-CuS) for induction of apoptosis of CT26 cells and activation of dendritic cells
Quantification of LPS coated onto the NPs was performed by measuring the UV absorption of fluorescein isothiocyanate (FITC)-labeled LPS-CuS

Summary

Introduction

To achieve success in cancer therapy, great endeavors have been devoted to cancer research all around the world. Notwithstanding these efforts, metastasis is the main obstacle for the complete treatment of cancer, and it causes majority of death due to cancer because metastatic cancer is hard to diagnosis and treat [1]. Various types of immunotherapy have been developed for and applied in cancer therapy including monoclonal antibody immunotherapy [3], adoptive cell transfer [4], checkpoint-blockade therapy [5], and cancer vaccines [6, 7]. A www.impactjournals.com/oncotarget new type of immunotherapy that can be applied to various different conditions with high specificity is needed

Objectives

Methods

Results

Discussion

Conclusion